Sjogren's Syndrome: Too many patients to ignore : Market Research Report

Sjogren's Syndrome: Too many patients to ignore

Published by: Datamonitor

Published: May. 28, 2002 - 26 Pages

EXECUTIVE SUMMARY

Introduction

Disease Etiology

Autoimmunity

Genetic factors

Environmental and chemical triggers

Epidemiology

Prevalence

Gender specificity

Age specificity

Diagnosis of Sjögren's syndrome

Diagnosis of keratoconjonctivitis sicca

Diagnosis of xerostomia

Identification of characterisitc autoantibodies

Additional tests

Symptoms of Sjögren's syndrome

Treatment of Sjögren's syndrome

Topical treatments

Systemic treatments

New treatment approaches to the stimulation of salivary and lacrimal functions

Unmet Needs in Sjögren's syndrome Therapy

Future Outlook

Product pipeline

Cyclosporine ophthalmic

INS365

Oral interferon alpha

Future market potential

Appendix

List of Figures

List of Tables

ABOUT DATAMONITOR

© Datamonitor 2002. All Rights Reserved.

Abstract

Introduction: Sjögren's Syndrome: Too Many Patients to Ignore, evaluates the current patient population, treatment options, and market potential for Sjögren's Syndrome, the second most common autoimmune musculoskeletal disease. The analysis details the epidemiology, diagnosis, and treatment patterns, and identifies unmet needs and potential licensing opportunities for companies looking to expand their musculoskeletal drug portfolio.

Scope of this Report:
* Interviewes with rheumatologists and primary care physicians to determine diagnosis and initial treatment patterns
* Extensive coverage of company press releases and annual reports, and additional secondary sources for product pipeline
* Unmet needs and treatment patterns identified by rheumatologists utilized to determine potential strategies for companies entering market.

Report Highlights: Sjögren’s Syndrome patients face two disadvantages. First, available treatments do not adequately treat the symptoms of the disease. Second, because of low patient and physician awareness, treatment generally starts at a late stage. As a result, significant room for improvement exists, creating a potential for commercial success. The Sjögren's syndrome market holds interesting commercial opportunities for pharmaceutical companies, particularly those looking to supplement their musculoskeletal franchises. Current products in the pipeline represent varying levels of opportunity for licensing success.

Key Reasons to Buy this Report:
* Identify potential licensing opportunities in the product pipeline
* Understand unmet needs in this underpublicized disease, including different forms of applicable treatment
* Consider expanding musculoskeletal pipeline through expanded indications or product development.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Sjogren's Syndrome: Too many patients to ignore

Table of Contents

Abstract